相关实验视频

Updated: Apr 13, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

新型单克隆抗体和Rituximab对NMOSD的实际有效性和耐受性

Zarmina Javed¹, Mengke Du², Mary Rensel¹

¹Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Annals of clinical and translational neurology

|August 29, 2025

概括

新型单克隆抗体 (nMAb) 对水素-4 IgG+ 神经脊髓炎光谱障碍 (NMOSD) 具有较高的有效性和耐受性,复发率低于rituximab.

科学领域:

神经免疫学
临床神经学
药理学

背景情况:

水素IgG+神经脊髓炎光谱障碍 (NMOSD) 是一种严重的自身免疫性疾病.
目前的治疗包括Rituximab,但新型单克隆抗体 (nMAb) 提供了新的治疗途径.

研究的目的:

在NMOSD患者中比较Rituximab与新型单克隆抗体 (nMAb) 的有效性和耐受性.
评估不同疗法治疗的患者的复发率和新的MRI病变.

主要方法:

多中心回顾性队列研究.
对135名接受Rituximab,Eculizumab,Inebilizumab或Satralizumab治疗的NMOSD患者进行分析.
评估复发的发生,没有复发的概率,以及新的MRI病变.

主要成果:

相比于rituximab,nMAb疗法 (inebilizumab,eculizumab,satralizumab) 显示出更好的复发预防能力.
在12个月内没有复发的概率为92% (rituximab),94% (inebilizumab) 和100% (eculizumab,satralizumab).
与Rituximab相比,用伊内比利兹马布治疗的患者的MRI病变较少;任何治疗都没有报告严重的不良反应.

结论:

新型单克隆抗体是水素-4 IgG+ NMOSD 的有效和耐受性良好的一线治疗方法.
nMAb疗法显著降低了复发率和新的病变的发展.
这些发现支持使用nMAb作为NMOSD的首选治疗策略.

关键词:

在NMOSD 有效性单克隆抗体其他药物耐受性

更多相关视频

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

相关概念视频

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...